Antinuclear Antibody Test Market - Forecast(2024 - 2030)
Overview
Antinuclear Antibody Test Market is projected to reach revenue of $2.35billion by 2025, and is estimated to grow at a CAGR of 12.4% during the forecast period 2019-2025. The Antinuclear Antibody test market size, in 2018, is $1.04 billion. Antinuclear Antibody tests are done to evaluate an individual for autoimmune disorders. Antinuclear antibodies (ANA) are produced as an immune response to foreign bodies. Sometimes these ANAs attack the cells within the body which leads to autoimmune disorders such as lupus, scleroderma, and rheumatoid arthritis. These ANAs are also called autoantibodies.
Key Takeaways
- The market is estimated to grow at a CAGR of 12.4%. With rising prevalence of autoimmune disorders, antinuclear antibody testing has also risen.
- Rising awareness and availability of range of diagnostic tools contribute to the growth in this market. Advances in technology and increasing investment in healthcare is also driving the market.
Test Product - Segment Analysis
Reagent assay kits occupy
the largest share in the antinuclear antibody test market. Laboratories
commonly use reagent assay kits to test for antibodies. These reagent assays
are popularly used as they are convenient, efficient, and accurate.
Test Technique - Segment Analysis
As per the technique of
antinuclear antibody test, ELISA (enzyme linked immunosorbent assay) has the
major share. This is due to the frequent use of this test for autoimmune
disorder tests. It detects and measures the antibodies from blood and hence is
convenient. ELISA is commonly used for detecting diseases such as HIV, Lyme
disease, and others.
Test Application - Segment Analysis
Rheumatoid arthritis segment
is estimated to have the largest share by test application and is growing at a CAGR
of 9.70%. This disease is highly prevalent and affects mostly those within the
age group of 35-50. Women are more likely to get this disease as compared to
men.
Test End-Use - Segment Analysis
The hospital segment is said
to have the highest share by test end-use. Hospitals are most frequented by
patients and thus a large number of tests are being conducted here compared to
clinics and laboratories.
Geography - Segment Analysis
North America accounts for
largest Antinuclear Antibody test market share with 35% in 2018. According to
the American Autoimmune Related Diseases Association, 50 million Americans have
Autoimmune Diseases. This huge number is said to contribute to growth in the
antinuclear antibody test market as larger number of tests will be done by
these patients.
Drivers – Antinuclear Antibody Test Market
- Rising prevalence of autoimmune diseases globally
Antibodies
protect body by strengthening the immune system. However, if a test detects antinuclear
antibodies in the body of an individual, it could mean that the person has an
autoimmune disorder. An antinuclear antibodies test is used to help diagnose
autoimmune disorders. As per the National Institutes of Health, about 23.5 million
Americans are affected by autoimmune diseases. Also, the Connect Immune
Research reports that costs for just 3 autoimmune diseases, namely, type 1
diabetes, rheumatoid arthritis and multiple sclerosis, add up to more than £13
billion per year in UK. Rising incidence of autoimmune disease have led to growth
of the antinuclear antibody test market.
- Advances in technology and research developments
Discovery of
biomarkers and laboratory automation is also said to drive the market. Biomarkers
are useful in identifying the diseases type, progression and more. Thus they
are useful in developing tests for the autoimmune diseases. Also with rising
autoimmune diseases, a number of samples are being used in their tests. Thus laboratory
automation is also crucial in handling these samples with accuracy and
efficiency.
Antinuclear Antibody Test Industry Outlook
Research & development along
with strategic alliances are some of the key strategies adopted by players in
the Antinuclear Antibody test market. Antinuclear Antibody Test Market top 10
companies are Alere Inc., Bio-Rad Laboratories, Inc., ERBA Diagnostics, Inc.,
Trinity Biotech plc, Thermo Fisher Scientific, Inc., Antibodies, Inc., Inova
Diagnostics, Zeus Scientific, Inc., F. Hoffmann-La Roche Ltd., and Becton
Dickinson and Company.
Antinuclear Antibody Test Market Research Scope:
The base year of the study
is 2018, with forecast done up to 2025. The study presents a thorough analysis
of the competitive landscape, taking into account the market shares of the
leading companies. These provide the key market participants with the necessary
business intelligence and help them understand the future of the Antinuclear
Antibody Test Market. The assessment includes the forecast, an overview of the
competitive structure, the market shares of the competitors, as well as the
market trends, market demands, market drivers, market challenges, and product
analysis. The market drivers and restraints have been assessed to fathom their
impact over the forecast period. This report further identifies the key
opportunities for growth while also detailing the key challenges and possible
threats.